CN104244965A - 治疗癌症和其它病症的纳米结构 - Google Patents

治疗癌症和其它病症的纳米结构 Download PDF

Info

Publication number
CN104244965A
CN104244965A CN201380017827.7A CN201380017827A CN104244965A CN 104244965 A CN104244965 A CN 104244965A CN 201380017827 A CN201380017827 A CN 201380017827A CN 104244965 A CN104244965 A CN 104244965A
Authority
CN
China
Prior art keywords
cholesterol
cells
hdl
nanostructures
synthetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380017827.7A
Other languages
English (en)
Chinese (zh)
Inventor
C·S·萨克森
M·G·达米安诺
张恒
K·M·麦克马洪
杨朔
L·I·乔丹
A·T·K·辛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Northwestern University
Original Assignee
Northwestern University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northwestern University filed Critical Northwestern University
Publication of CN104244965A publication Critical patent/CN104244965A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ceramic Engineering (AREA)
  • Physics & Mathematics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Optics & Photonics (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
CN201380017827.7A 2012-02-22 2013-02-22 治疗癌症和其它病症的纳米结构 Pending CN104244965A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261601706P 2012-02-22 2012-02-22
US61/601,706 2012-02-22
PCT/US2013/027431 WO2013126776A1 (en) 2012-02-22 2013-02-22 Nanostructures for treating cancers and other conditions

Publications (1)

Publication Number Publication Date
CN104244965A true CN104244965A (zh) 2014-12-24

Family

ID=47833440

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201380017827.7A Pending CN104244965A (zh) 2012-02-22 2013-02-22 治疗癌症和其它病症的纳米结构

Country Status (11)

Country Link
US (1) US20150064255A1 (enExample)
EP (2) EP3597209A1 (enExample)
JP (1) JP2015513543A (enExample)
KR (1) KR20140123597A (enExample)
CN (1) CN104244965A (enExample)
AU (1) AU2013222238A1 (enExample)
CA (1) CA2865279C (enExample)
ES (1) ES2745208T3 (enExample)
IN (1) IN2014DN07888A (enExample)
MX (1) MX2014010161A (enExample)
WO (1) WO2013126776A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112569207A (zh) * 2019-09-30 2021-03-30 复旦大学 一种载脂蛋白修饰的仿生纳米肿瘤疫苗及其制备方法和用途
CN113939278A (zh) * 2019-04-26 2022-01-14 西北大学 用于眼部疗法的高密度脂蛋白纳米颗粒和rna模板化脂蛋白颗粒

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5204646B2 (ja) 2005-04-25 2013-06-05 マサチューセッツ インスティテュート オブ テクノロジー 止血および他の生理学的活性を促進するための組成物および方法
ES2673947T3 (es) 2006-04-25 2018-06-26 Massachusetts Institute Of Technology Composiciones y métodos para afectar al movimiento de contaminantes, líquidos corporales u otras entidades y/o afectar a otras condiciones fisiológicas
CN102036652B (zh) 2008-04-25 2016-04-13 西北大学 适于螯合胆甾醇的纳米结构
US9439941B2 (en) 2009-12-14 2016-09-13 The University Of Hong Kong Nano cancer barrier device (NCBD) to immobilize and inhibit the division of metastic cancer stem cells
US20130034599A1 (en) 2010-01-19 2013-02-07 Northwestern University Synthetic nanostructures including nucleic acids and/or other entities
CA2831613A1 (en) 2011-03-31 2012-10-04 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
EP4144378A1 (en) 2011-12-16 2023-03-08 ModernaTX, Inc. Modified nucleoside, nucleotide, and nucleic acid compositions
DK2922554T3 (en) 2012-11-26 2022-05-23 Modernatx Inc Terminalt modificeret rna
JP2016504050A (ja) 2013-01-17 2016-02-12 モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． 細胞表現型の改変のためのシグナルセンサーポリヌクレオチド
EP2971010B1 (en) 2013-03-14 2020-06-10 ModernaTX, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
KR20160042917A (ko) 2013-07-25 2016-04-20 엑시큐어, 인크. 예방 및 치료 용도를 위한 면역자극제로서의 구형 핵산-기재 구축물
US10568898B2 (en) 2013-08-13 2020-02-25 Northwestern University Lipophilic nanoparticles for drug delivery
US10413565B2 (en) 2014-04-30 2019-09-17 Northwestern University Nanostructures for modulating intercellular communication and uses thereof
WO2016011049A2 (en) * 2014-07-14 2016-01-21 Schwendeman Anna Compositions and methods for disease treatment using nanoparticle delivered compounds
WO2016057549A1 (en) 2014-10-06 2016-04-14 Aurasense Therapeutics, Llc Anti-tnf compounds
US10517924B2 (en) * 2014-11-24 2019-12-31 Northwestern University High density lipoprotein nanoparticles for inflammation
WO2016123365A1 (en) 2015-01-30 2016-08-04 The Regents Of The University Of Michigan Liposomal particles comprising biological molecules and uses thereof
US10078092B2 (en) 2015-03-18 2018-09-18 Northwestern University Assays for measuring binding kinetics and binding capacity of acceptors for lipophilic or amphiphilic molecules
EP3273944B1 (en) 2015-03-25 2024-11-20 The Regents of The University of Michigan Compositions and methods for delivery of biomacromolecule agents
US10967072B2 (en) 2016-04-27 2021-04-06 Northwestern University Short interfering RNA templated lipoprotein particles (siRNA-TLP)
US12257352B2 (en) 2016-06-20 2025-03-25 The Regents Of The University Of Michigan Compositions and methods for delivery of biomacromolecule agents
WO2020154705A1 (en) * 2019-01-24 2020-07-30 Northwestern University High-density lipoprotein mimetic nanoparticles using lipid conjugated core scaffolds
US20220218788A1 (en) * 2019-05-10 2022-07-14 Northwestern University Orally delivered lipid nanoparticles target and reveal gut cd36 as a master regulator of systemic lipid homeostasis with differential gender responses
US20220331445A1 (en) * 2019-09-18 2022-10-20 Northwestern University High density lipoprotein-like nanoparticles as inducers of ferroptosis in cancer
WO2023243865A1 (ko) * 2022-06-13 2023-12-21 (주) 멥스젠 약물전달용 재구축 고밀도 지단백 나노입자

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007089607A2 (en) * 2006-01-26 2007-08-09 University Of Massachusetts Rna silencing agents for use in therapy and nanotransporters for efficient delivery of same
CN102036652A (zh) * 2008-04-25 2011-04-27 西北大学 适于螯合胆甾醇的纳米结构
WO2011091065A2 (en) * 2010-01-19 2011-07-28 Northwestern University Synthetic nanostructures including nucleic acids and/or other entities

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110020242A1 (en) * 2007-12-12 2011-01-27 Gang Zheng High-density lipoprotein-like peptide-phospholipid scaffold ("hpps") nanoparticles

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007089607A2 (en) * 2006-01-26 2007-08-09 University Of Massachusetts Rna silencing agents for use in therapy and nanotransporters for efficient delivery of same
CN102036652A (zh) * 2008-04-25 2011-04-27 西北大学 适于螯合胆甾醇的纳米结构
WO2011091065A2 (en) * 2010-01-19 2011-07-28 Northwestern University Synthetic nanostructures including nucleic acids and/or other entities

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CARLOS G.LEON,ET AL: "Alterations in Cholesterol Regulation Contribute to the Production of Intratumoral Androgens During Progression to Castration-Resistant Prostate Cancer in a Mouse Xenograft Model", 《THEPROSTATE》 *
ROMELIA PINHEIRO GONCALVES，ET AL: "Uptake of high density lipoprotein (HDL) cholesteryl esters by human acute leukemia cells", 《LEUKEMIA RESEARCH》 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113939278A (zh) * 2019-04-26 2022-01-14 西北大学 用于眼部疗法的高密度脂蛋白纳米颗粒和rna模板化脂蛋白颗粒
CN112569207A (zh) * 2019-09-30 2021-03-30 复旦大学 一种载脂蛋白修饰的仿生纳米肿瘤疫苗及其制备方法和用途

Also Published As

Publication number Publication date
JP2015513543A (ja) 2015-05-14
EP2817024B1 (en) 2019-07-10
EP3597209A1 (en) 2020-01-22
IN2014DN07888A (enExample) 2015-04-24
KR20140123597A (ko) 2014-10-22
WO2013126776A1 (en) 2013-08-29
ES2745208T3 (es) 2020-02-28
MX2014010161A (es) 2015-03-09
US20150064255A1 (en) 2015-03-05
AU2013222238A1 (en) 2014-09-18
EP2817024A1 (en) 2014-12-31
CA2865279C (en) 2023-04-25
CA2865279A1 (en) 2013-08-29

Similar Documents

Publication Publication Date Title
CN104244965A (zh) 治疗癌症和其它病症的纳米结构
Zhou et al. Tumour‐derived extracellular vesicle membrane hybrid lipid nanovesicles enhance siRNA delivery by tumour‐homing and intracellular freeway transportation
KR102585143B1 (ko) 폴리글루타메이트화 항엽산 및 이의 용도
JP5863670B2 (ja) 核酸および／または他の構成要素を含有している合成ナノ構造体
EP2120876B1 (en) Nanoparticle delivery systems for membrane-integrating peptides
Bonnaud et al. Sphingosine-1-phosphate activates the AKT pathway to protect small intestines from radiation-induced endothelial apoptosis
US20110177155A1 (en) Methods of delivery of agents to leukocytes and endothelial cells
CN117159470A (zh) 脂质体包封的亲和性药物
Mu et al. Lipid vesicles containing transferrin receptor binding peptide TfR-T12 and octa-arginine conjugate stearyl-R8 efficiently treat brain glioma along with glioma stem cells
JP2016529284A (ja) ナノ粒子薬物デリバリシステムおよび、癌および神経外傷の治療方法
US11969396B2 (en) IPA-3-loaded liposomes and methods of use thereof
Ma et al. High-affinity human anti-c-Met IgG conjugated to oxaliplatin as targeted chemotherapy for hepatocellular carcinoma
US10413565B2 (en) Nanostructures for modulating intercellular communication and uses thereof
WO2015168393A1 (en) Nanostructures for modulating intercellular communication and uses thereof
Gholizadeh et al. Anti-GD2 immunoliposomes for delivery of the survivin inhibitor Sepantronium bromide (YM155) to neuroblastoma tumor cells
OA19187A (en) Polyglutamated antifolates and uses thereof.
HK1139053B (en) Nanoparticle delivery systems for membrane-integrating peptides

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20141224